These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 6493446)
1. Effect of vertebral, carotid and intravenous infusions of lysine vasopressin on plasma vasopressin and cardiovascular function. Brooks DP; Share L; Crofton J; Matsui K; Rockhold RW Neuroendocrinology; 1984 Oct; 39(4):350-5. PubMed ID: 6493446 [TBL] [Abstract][Full Text] [Related]
2. The cardiovascular response to vertebral artery infusions of angiotensin in the dog. Lowe RD; Scroop GC Clin Sci; 1969 Dec; 37(3):593-603. PubMed ID: 4312145 [No Abstract] [Full Text] [Related]
3. Cardiovascular effects of vasopressin infused into the vertebral circulation of conscious dogs. Liard JF; Dériaz O; Tschopp M; Schoun J Clin Sci (Lond); 1981 Sep; 61(3):345-7. PubMed ID: 7261556 [TBL] [Abstract][Full Text] [Related]
4. Vasopressin dilates the rat carotid artery by stimulating V1 receptors. Rutschmann B; Evequoz D; Aubert JF; Brunner HR; Waeber B J Cardiovasc Pharmacol; 1998 Oct; 32(4):637-41. PubMed ID: 9781933 [TBL] [Abstract][Full Text] [Related]
5. The cardiovascular effects of intravertebral angiotensin II before and after treatment with clonidine. Lumbers ER; Reid IA Clin Exp Pharmacol Physiol; 1981; 8(5):531-5. PubMed ID: 7326876 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of prostaglandins mediated by the central nervous system of the dog. Lavery HA; Lowe RD; Scroop GC Br J Pharmacol; 1970 Jul; 39(3):511-9. PubMed ID: 5472202 [TBL] [Abstract][Full Text] [Related]
7. Thromboxane A2 acts at a site perfused by the carotid vasculature to mediate cardiovascular and adrenocortical responses. Cudd TA; Castellon R; Purinton SC Can J Physiol Pharmacol; 1997 Apr; 75(4):271-8. PubMed ID: 9196852 [TBL] [Abstract][Full Text] [Related]
8. The release of vasopressin by nicotine: further studies on its site of action. Castro de Souza E; Rocha E Silva M J Physiol; 1977 Feb; 265(2):297-311. PubMed ID: 850196 [TBL] [Abstract][Full Text] [Related]
9. Neurohypophysial peptides and central cardiovascular control. Montastruc JL; Dang Tran L; Montastruc P Eur Heart J; 1983 Nov; 4 Suppl G():47-50. PubMed ID: 6662121 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of putrescine in dogs after systemic, intra-arterial vertebral and intraventricular injection. Rossi F; Nisticò G; De Marco G; Berrino L; Matera C; Bile G; Marmo E Res Commun Chem Pathol Pharmacol; 1984 Oct; 46(1):43-52. PubMed ID: 6505389 [TBL] [Abstract][Full Text] [Related]
11. Comparison of vasopressin and triglycyl-lysine vasopressin on splanchnic and systemic hemodynamics in dogs. Blei AT; Groszmann RJ; Gusberg R; Conn HO Dig Dis Sci; 1980 Sep; 25(9):688-94. PubMed ID: 7418592 [TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of exogenous and endogenous vasopressin at low plasma concentrations in conscious dogs. Montani JP; Liard JF; Schoun J; Möhring J Circ Res; 1980 Sep; 47(3):346-55. PubMed ID: 7408117 [TBL] [Abstract][Full Text] [Related]
13. Adverse cardiodynamic effects of vasopressin not avoided by selective intra-arterial administration. Sirinek KR; Thomford NR; Pace WG Surgery; 1977 Jun; 81(6):723-8. PubMed ID: 860202 [TBL] [Abstract][Full Text] [Related]
14. Exogenous arginine vasopressin does not enhance carotid baroreflex control in the conscious dog. Wolfer RS; Lovell NH; Brunner MJ Am J Physiol; 1994 May; 266(5 Pt 2):R1510-6. PubMed ID: 8203628 [TBL] [Abstract][Full Text] [Related]